Resistance stayed moderate in cell culture
RSM01, an antibody being developed against respiratory syncytial virus (RSV), showed a high resistance barrier in laboratory research published in the peer-reviewed journal Nature Communications. RSV is a respiratory virus of particular concern in young children. Resistant variants appeared infrequently with RSM01 and their resistance remained moderate. The work measured viral susceptibility in cultured cells; protection in infants requires clinical research.[1], [2]
The candidate is a monoclonal antibody, a laboratory-developed antibody of one type, designed to remain active for an extended period. Its development programme focuses on low- and middle-income countries, where RSV imposes a substantial burden of infant illness and mortality. The earlier laboratory attempts to obtain resistant variants had been unsuccessful. The new investigation compared RSM01 with the licensed antibodies nirsevimab and palivizumab. Both comparators were associated with highly resistant variants in the laboratory comparison, while RSM01 showed the more limited resistance pattern.[1], [2]
